KR20090064463A - 카텝신 프로테아제 억제제 - Google Patents

카텝신 프로테아제 억제제 Download PDF

Info

Publication number
KR20090064463A
KR20090064463A KR1020097008318A KR20097008318A KR20090064463A KR 20090064463 A KR20090064463 A KR 20090064463A KR 1020097008318 A KR1020097008318 A KR 1020097008318A KR 20097008318 A KR20097008318 A KR 20097008318A KR 20090064463 A KR20090064463 A KR 20090064463A
Authority
KR
South Korea
Prior art keywords
compound
cathepsin
optionally substituted
mmol
pharmaceutically acceptable
Prior art date
Application number
KR1020097008318A
Other languages
English (en)
Korean (ko)
Inventor
로버트 에플
로스 루소
Original Assignee
아이알엠 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이알엠 엘엘씨 filed Critical 아이알엠 엘엘씨
Publication of KR20090064463A publication Critical patent/KR20090064463A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020097008318A 2006-10-23 2007-10-17 카텝신 프로테아제 억제제 KR20090064463A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86250006P 2006-10-23 2006-10-23
US60/862,500 2006-10-23

Publications (1)

Publication Number Publication Date
KR20090064463A true KR20090064463A (ko) 2009-06-18

Family

ID=39091868

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097008318A KR20090064463A (ko) 2006-10-23 2007-10-17 카텝신 프로테아제 억제제

Country Status (9)

Country Link
EP (1) EP2078027A1 (fr)
JP (1) JP2010507681A (fr)
KR (1) KR20090064463A (fr)
CN (1) CN101589047A (fr)
AU (1) AU2007309195A1 (fr)
BR (1) BRPI0717348A2 (fr)
CA (1) CA2667816A1 (fr)
MX (1) MX2009004290A (fr)
WO (1) WO2008051763A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744987C (fr) 2008-12-02 2018-01-16 Chiralgen, Ltd. Procede pour la synthese d'acides nucleiques modifies par des atomes de phosphore
CA2767253A1 (fr) 2009-07-06 2011-01-13 Ontorii, Inc. Nouveaux precurseurs d'acide nucleique et leurs methodes d'utilisation
EP2620428B1 (fr) * 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Groupe auxiliaire asymétrique
EP3248982A1 (fr) 2011-07-19 2017-11-29 Wave Life Sciences Ltd. Reactifs de type thiosulfonate pour la synthèse d'acides nucléiques fonctionnalisés
EP4219516A3 (fr) 2012-07-13 2024-01-10 Wave Life Sciences Ltd. Controle chiral
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
RU2016133035A (ru) 2014-01-16 2018-02-21 Уэйв Лайф Сайенсес Лтд. Хиральный дизайн
US10017463B2 (en) 2014-07-21 2018-07-10 Brandeis University Inhibitors of deubiquitinating proteases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7297714B2 (en) * 2003-10-21 2007-11-20 Irm Llc Inhibitors of cathepsin S

Also Published As

Publication number Publication date
MX2009004290A (es) 2009-07-27
CN101589047A (zh) 2009-11-25
WO2008051763A1 (fr) 2008-05-02
JP2010507681A (ja) 2010-03-11
BRPI0717348A2 (pt) 2013-10-15
EP2078027A1 (fr) 2009-07-15
AU2007309195A1 (en) 2008-05-02
CA2667816A1 (fr) 2008-05-02

Similar Documents

Publication Publication Date Title
KR20090064463A (ko) 카텝신 프로테아제 억제제
US10882855B2 (en) Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases
US20230084249A1 (en) Compounds and methods for the targeted degradation of androgen receptor and associated methods of use
JP2002518368A (ja) メタロプロテイナーゼ阻害剤としての環式ヒドロキサム酸類
US8003653B2 (en) Imidazolidinone compounds useful as β-secretase inhibitors for the treatment of Alzheimer's disease
CZ290095A3 (en) Hiv protease inhibitors and pharmaceutical compositions containing thereof
CZ36299A3 (cs) Inhibitory cystein proteasy
EA012810B1 (ru) Димерные ингибиторы ингибиторов белков апоптоза (iap)
ES2331102T3 (es) Compuestos con propiedades de liberacion de la hormona del crecimiento.
JP6337750B2 (ja) 化合物
JP7130873B2 (ja) バニン阻害剤としてのヘテロ芳香族化合物
US9000182B2 (en) 2H-imidazol-4-amine compounds and their use as BACE inhibitors
TW200924790A (en) Macrocyclic inhibitors of hepatitis C virus NS3 serine protease
TW200825056A (en) New compounds
JP6333267B2 (ja) アザインドリン
CA2223500A1 (fr) Inhibiteurs de thrombine
WO2009038411A2 (fr) Composés inhibiteurs de la béta-sécrétase contenant un fragment d'oxo-dihydro-pyrazole
Hanessiana et al. P1, P3 truncated analogs of oscillarin and their inhibitory activity against blood coagulation factors
WO2024054876A1 (fr) Composés de dégradation de kinase à séquence répétée riche en leucine 2 (lrrk2) et méthodes d'utilisation associées
WO2010087471A1 (fr) Dérivés d'hydroxypyrazinecarboxamide
EP1911762A1 (fr) aminoalcools et leurs utilisation comme inhibiteurs de rénine

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application